Wheel vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wheel is a telehealth infrastructure company providing the clinician network, technology, and operations that companies need to build and scale virtual care programs.
About
Wheel is a telehealth infrastructure company founded in 2017 that provides the clinical workforce, technology platform, and operational services that enable businesses to build and power virtual care programs. The company operates as a B2B platform serving healthcare companies, retailers, insurers, and employers that want to offer telehealth services without building a clinical workforce from scratch. Wheel provides access to a nationwide network of licensed clinicians including physicians, nurse practitioners, and physician assistants who can be deployed to power telehealth products across medical, behavioral health, and chronic care specialties. The platform handles clinician credentialing, scheduling, documentation workflows, and state licensure management so that clients can focus on patient experience and growth. Wheel raised over $160M and has powered telehealth programs for companies including retailers launching pharmacy and health clinics and digital health companies scaling their clinical capacity rapidly. As telehealth has become embedded in mainstream healthcare delivery, Wheel enables organizations to participate in virtual care without the complexity of building clinical operations infrastructure internally.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.